Vaxart (VXRT) announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine ...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the ...

A new trial that aims to protect against norovirus, a highly contagious stomach bug that causes vomiting and diarrhoea, is ...

In a world first, a norovirus vaccine is set to be trialled in the UK. Norovirus is a common bug that causing vomiting and diarrhoea and is easily spread, affecting people of all ages. Due to its ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.78 which represents a decrease of $-0.04 or -4.88% from the prior close of $0.82. The stock opened at $0.81 and touched a low of ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.77 which represents a decrease of $-0.02 or -2.53% from the prior close of $0.79. The stock opened at $0.79 and touched a low of ...

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Vaxart Inc. (Nasdaq: VXRT) develops oral vaccine pills designed to attack pathogens before they pass through the nose, mouth ...

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns. Vaxart Inc (VXRT) has experienced a -6.62% fall in stock performance for the ...

Cash Runway: Anticipated to extend into 2026 based on current plans. Vaxart Inc (NASDAQ:VXRT) received a significant BARDA contract valued at up to $453 million under Project NextGen, highlighting the ...